2022-08-01 2023-07-31 false Capium Accounts Production 1.1 08162336 bus:AbridgedAccounts 2022-08-01 2023-07-31 08162336 bus:FRS102 2022-08-01 2023-07-31 08162336 bus:AuditExemptWithAccountantsReport 2022-08-01 2023-07-31 08162336 bus:SmallCompaniesRegimeForAccounts 2022-08-01 2023-07-31 08162336 bus:PrivateLimitedCompanyLtd 2022-08-01 2023-07-31 08162336 2022-08-01 2023-07-31 08162336 2023-07-31 08162336 bus:RegisteredOffice 2022-08-01 2023-07-31 08162336 core:WithinOneYear 2023-07-31 08162336 core:AfterOneYear 2023-07-31 08162336 bus:Director1 2022-08-01 2023-07-31 08162336 bus:Director1 2023-07-31 08162336 bus:Director1 2021-08-01 2022-07-31 08162336 2021-08-01 08162336 bus:CompanySecretary1 2022-08-01 2023-07-31 08162336 bus:LeadAgentIfApplicable 2022-08-01 2023-07-31 08162336 2021-08-01 2022-07-31 08162336 2022-07-31 08162336 core:WithinOneYear 2022-07-31 08162336 core:AfterOneYear 2022-07-31 08162336 bus:EntityAccountantsOrAuditors 2021-08-01 2022-07-31 08162336 bus:OrdinaryShareClass1 2022-08-01 2023-07-31 08162336 bus:OrdinaryShareClass1 2023-07-31 08162336 bus:OrdinaryShareClass1 2021-08-01 2022-07-31 08162336 bus:OrdinaryShareClass1 2022-07-31 08162336 core:ComputerEquipment 2022-08-01 2023-07-31 08162336 core:ComputerEquipment 2023-07-31 08162336 core:ComputerEquipment 2022-07-31 08162336 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-07-31 08162336 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2022-07-31 08162336 core:CostValuation core:Non-currentFinancialInstruments 2023-07-31 08162336 core:CostValuation core:Non-currentFinancialInstruments 2022-07-31 08162336 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2023-07-31 08162336 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2023-07-31 08162336 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2023-07-31 08162336 core:Non-currentFinancialInstruments 2023-07-31 08162336 core:Non-currentFinancialInstruments 2022-07-31 08162336 core:ShareCapital 2023-07-31 08162336 core:ShareCapital 2022-07-31 08162336 core:RetainedEarningsAccumulatedLosses 2023-07-31 08162336 core:RetainedEarningsAccumulatedLosses 2022-07-31 08162336 dpl:Item1 2022-08-01 08162336 dpl:Item1 2023-07-31 08162336 dpl:Item1 2021-08-01 08162336 dpl:Item1 2022-07-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 08162336
England

 

 

 

RRF MEDICAL LTD


Abridged Accounts
 


Period of accounts

Start date: 01 August 2022

End date: 31 July 2023
Report to the directors on the preparation of the unaudited statutory accounts of RRF MEDICAL LTD for the year ended 31 July 2023
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of RRF MEDICAL LTD for the year ended 31 July 2023 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company’s accounting records and from information and explanations you have given us
As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at
http://rulebook.accaglobal.com/
This report is made solely to the Board of Directors of RRF MEDICAL LTD, as a body, in accordance with the terms of our engagement letter dated 01 May 2024 Our work has been undertaken solely to prepare for your approval the accounts of RRF MEDICAL LTD and state those matters that we have agreed to state to the Board of Directors of RRF MEDICAL LTD, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than RRF MEDICAL LTD and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that RRF MEDICAL LTD has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of RRF MEDICAL LTD. You consider that RRF MEDICAL LTD is exempt from the statutory audit requirement for the year
We have not been instructed to carry out an audit or a review of the accounts of RRF MEDICAL LTD. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts
31 July 2023



....................................................
SAW Accounting & Tax Advisory Limited
Suite Ss, Avon House
435 Stratford Road
B90 4AA
01 May 2024
1
 
 
Notes
 
2023
£
  2022
£
Fixed assets      
Tangible fixed assets 3 10,500   
10,500   
Current assets      
Debtors 25,000    96,191 
Cash at bank and in hand 30,822    2,631 
55,822    98,822 
Creditors: amount falling due within one year (66,050)   (94,662)
Net current assets (10,228)   4,160 
 
Total assets less current liabilities 272    4,160 
Net assets 272    4,160 
 

Capital and reserves
     
Called up share capital 4 100    100 
Profit and loss account 172    4,060 
Shareholder's funds 272    4,160 
 


For the year ended 31 July 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 01 May 2024 and were signed by:


-------------------------------
Dr Rachel Rose Ford
Director
2
General Information
RRF MEDICAL LTD is a private company, limited by shares, registered in England, registration number 08162336, registration address Leicester Lodge, Markfield Lane, LE9 9FH.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment 3 Years Straight Line
2.

Average number of employees

Average number of employees during the year was 1 (2022 : 1).
3.

Tangible fixed assets

Cost or valuation Computer Equipment   Total
  £   £
At 01 August 2022  
Additions 10,500    10,500 
Disposals  
At 31 July 2023 10,500    10,500 
Depreciation
At 01 August 2022  
Charge for year  
On disposals  
At 31 July 2023  
Net book values
Closing balance as at 31 July 2023 10,500    10,500 
Opening balance as at 01 August 2022  


4.

Share Capital

Allotted, called up and fully paid
2023
£
  2022
£
100 Class A shares of £1.00 each 100    100 
100    100 

3